文献速递传染病防控与疫情报告免疫规划

重组ORF2 p551蛋白免疫可保护普通狨猴抵抗同源与异源戊型肝炎病毒攻击

Immunization with recombinant ORF2 p551 protein protects common marmosets (Callithrix jacchus) against homologous and heterologous hepatitis E virus challenge.
PubMed 文献 · Vaccine · 2021-11-24

研究用大肠杆菌表达并纯化HEV基因3型pORF2的p551蛋白,形成27.71±2.42 nm病毒样颗粒,联合铝佐剂肌内注射免疫普通狨猴(n=4),对照仅佐剂(n=2)。免疫后抗HEV IgG平均滴度达1:1810,同源与异源HEV攻击后均未发生感染,而对照出现病毒排出和肝酶升高。

要点

  • p551蛋白可形成27.71±2.42 nm的病毒样颗粒,免疫后抗HEV IgG平均滴度1:1810。
  • 免疫狨猴在同源和异源HEV攻击后随访期间未发生HEV感染。
  • 对照狨猴感染HEV GT1和GT3后出现病毒排出和肝酶水平升高。

核心结论

  • 普通狨猴是对HEV GT1和GT3易感的便利实验室动物模型。
  • HEV GT3 ORF2/p551免疫可激发强效抗HEV抗体应答,保护狨猴抵抗同源与异源HEV攻击。
  • p551病毒样颗粒可作为HEV原型疫苗候选。

研究设计与样本

  • 将HEV GT3 pORF2第110-660位氨基酸对应的p551在大肠杆菌中表达并经亲和层析纯化。
  • 普通狨猴肌内注射20 μg p551病毒样颗粒加铝佐剂(n=4)或仅佐剂(n=2),于第0、3、7、19周免疫。
  • 第27周以HEV GT1或GT3攻击,随后纵向检测肝功能指标、抗HEV IgG及粪便和血清HEV RNA。

主要发现

  • 纯化p551形成粒径27.71±2.42 nm的病毒样颗粒。
  • 两次p551免疫诱导抗HEV IgG平均滴度1:1810。
  • 免疫狨猴在同源与异源HEV基因型攻击后随访期间未发生HEV感染。
  • 对照狨猴感染HEV GT1和GT3后出现病毒排出和肝酶水平升高。
  • 免疫狨猴及HEV感染已清除的对照狨猴抗HEV IgG高水平持续至攻击后两年。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis E virus (HEV) is a major causative agent of acute hepatitis worldwide, prompting continuous HEV vaccine efforts. Vaccine development is hampered by the lack of convenient animal models susceptible to infection with different HEV genotypes. We produced recombinant open reading frame 2 protein (pORF2; p551) of HEV genotype (GT) 3 and assessed its immunogenicity and protectivity against HEV challenge in common marmosets (Callithrix jacchus, CM). METHODS: p551 with consensus sequence corresponding to amino acid residues 110-660 of HEV GT3 pORF2 was expressed in E. coli and purified by affinity chromatography. CMs were immunized intramuscularly with 20 μg of p551 VLPs with alum adjuvant (n = 4) or adjuvant alone (n = 2) at weeks 0, 3, 7 and 19. At week 27, p551-immunized and control animals were challenged with HEV GT1 or GT3 and thereafter longitudinally screened for markers of liver function, anti-HEV IgG and HEV RNA in feces and sera. RESULTS: Purified p551 formed VLPs with particle size of 27.71 ± 2.42 nm. Two immunizations with p551 induced anti-HEV IgG mean titer of 1:1810. Immunized CMs challenged with homologous and heterologous HEV genotype did not develop HEV infection during the follow-up. Control CMs infected with both HEV GT1 and GT3 demonstrated signs of HEV infection with virus shedding and elevation of the levels of liver enzymes. High levels of anti-HEV IgG persisted in vaccinated CMs and control CMs that resolved HEV infection, for up to two years post challenge. CONCLUSIONS: CMs are shown to be a convenient laboratory animal model susceptible to infection with HEV GT1 and GT3. Immunization with HEV GT3 ORF2/p551 triggers potent anti-HEV antibody response protecting CMs from homologous and heterologous HEV challenge. This advances p551 in VLPs as a prototype vaccine against HEV.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gordeychuk I, Kyuregyan K, Kondrashova A, et al. Immunization with recombinant ORF2 p551 protein protects common marmosets (Callithrix jacchus) against homologous and heterologous hepatitis E virus challenge. Vaccine. 2021. PMID: 34836660. doi:10.1016/j.vaccine.2021.11.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。